Catalent Inhalation, a division of Catalent Pharma Solutions, has been engaged by Arch Biopartners, a Toronto-based therapeutic technology company, to begin manufacturing Arch's bactericidal compound, AB569, in preparation for human trials involving patients with antibiotic-resistant lung infections. Arch received orphan drug designation on AB569 from the US Food and Drug Administration in November 2015 for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients.

Catalent Inhalation will commence with initial stability and formulation studies. If these stages are completed with positive results, Arch will engage Catalent Inhalation to manufacture a supply of AB569 that meets GMP standards.

Source: Arch Biopartners